ADX-71149
ADX-71149, also known as JNJ-40411813 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu2 receptor. It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia. It was also researched by these companies for the treatment of anxious depression (major depressive disorder with anxiety symptoms), but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication. As of 2015, ADX-71149 is in phase II clinical trials for schizophrenia.
primaryTopic
ADX-71149
ADX-71149, also known as JNJ-40411813 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu2 receptor. It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia. It was also researched by these companies for the treatment of anxious depression (major depressive disorder with anxiety symptoms), but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication. As of 2015, ADX-71149 is in phase II clinical trials for schizophrenia.
has abstract
ADX-71149, also known as JNJ-4 ...... ical trials for schizophrenia.
@en
ATC prefix
CAS number
1127498-03-6
FDA UNII code
612BYT76F3
IUPAC name
1-Butyl-3-chloro-4-(4-phenylpiperidin-1-yl)-1,2-dihydropyridin-2-one
@en
PubChem
thumbnail
Link from a Wikipage to an external page
Wikipage page ID
46,790,356
Wikipage revision ID
735,714,395
ChEMBL
ChemSpiderID
28,424,210
IUPHAR ligand
smiles
CCCCN1C=CCN2CCCC3=CC=CC=C3
StdInChIKey
HYOGJHCDLQSAHX-UHFFFAOYSA-N
hypernym
comment
ADX-71149, also known as JNJ-4 ...... ical trials for schizophrenia.
@en
label
ADX-71149
@en
